Friday, November 6, 2020
- 9:00AM-11:00AM
-
Abstract Number: 0192
Influence of Inflammatory and Non-inflammatory Rheumatic Disorders on the Clinical and Biological Profile of Adult-onset Diabetes
RA – Diagnosis, Manifestations, & Outcomes Poster I: Multimorbidity- 9:00AM-11:00AM
-
Abstract Number: 0229
Integrated Safety of Filgotinib in Patients with Moderately or Severely Active Rheumatoid Arthritis Receiving Treatment for up to 5.5 Years
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0171
Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, T Cells, B Cells, and NK Cells in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI
Pediatric Rheumatology – Basic Science Poster- 9:00AM-11:00AM
-
Abstract Number: 0099
Interleukin 6 Concentration in Synovial Fluid of Patients with Different Types of Arthritis
Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing- 9:00AM-11:00AM
-
Abstract Number: 0335
Interleukin-17 Blockade Leads to Shifts from Stage-based Towards Response-based Disease Clusters- Comparative Data from Very Early and Established Psoriatic Arthritis
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 0296
Investigating the Differences in ANA Specificities Between Asymptomatic and Symptomatic ANA+ Individuals
SLE – Etiology & Pathogenesis Poster- 9:00AM-11:00AM
-
Abstract Number: 0219
Is It Realistic to Stop Prednisone in Early Rheumatoid Arthritis? A Subanalysis from the BeSt and IMPROVED Studies
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0339
Is Sex-adjusted Treatment in Early-PsA Justified?
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 0404
Isolated Aortitis: Single Centre Experience of Clinical Spectrum and Management
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I- 9:00AM-11:00AM
-
Abstract Number: 0378
Itch as the Major Mediator of the Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0019
Lasting COVID-19 Impacts on US Rheumatology Practices
Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease- 9:00AM-11:00AM
-
Abstract Number: 0037
Lipoprotein-associated Phospholipase A2: A New Biomarker for Lymphoma Development in Sjögren’s Syndrome
Genetics, Genomics & Proteomics Poster